7Baggers

Stoke Therapeutics Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Revenue  
 Operating Profit  
 Net Income  
20200930 20201231 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 20240331 20240630 20240930 20241231 20250331 20250630 -33.26-5.8621.5548.9576.36103.76131.16158.57Milllion

Stoke Therapeutics Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 
                           
  revenue13,817,000 158,569,000 22,614,000 4,894,000 4,831,000 4,216,000 2,802,000 3,308,000 -2,481,000 5,152,000 3,268,000 2,905,000 3,231,000 3,000,000            
  yoy186.01% 3661.12% 707.07% 47.94% -294.72% -18.17% -14.26% 13.87% -176.79% 71.73%                
  qoq-91.29% 601.20% 362.08% 1.30% 14.59% 50.46% -15.30% -233.33% -148.16% 57.65% 12.50% -10.09% 7.70%             
  operating expenses:                         
  research and development25,855,000 32,676,000 23,423,000 22,205,000 21,136,000 22,368,000 21,778,000 20,271,000 20,551,000 19,631,000 21,060,000 20,109,000 18,358,000 18,309,000 15,802,000 14,358,000 14,095,000 9,913,000 8,904,000 8,109,000 7,968,000 7,215,000 7,089,000 6,518,000 6,023,000 
  general and administrative15,262,000 14,653,000 12,844,000 12,692,000 13,037,000 10,220,000 10,610,000 10,271,000 10,230,000 10,211,000 9,384,000 9,944,000 10,111,000 9,486,000 8,724,000 8,325,000 7,934,000 6,914,000 5,682,000 5,602,000 5,044,000 4,520,000 3,979,000 3,324,000 2,422,000 
  total operating expenses41,117,000 47,329,000 36,267,000 34,897,000 34,173,000 32,588,000 32,388,000 30,542,000 30,781,000 29,842,000 30,444,000 30,053,000 28,469,000 27,795,000 24,526,000 22,683,000 22,029,000 16,827,000 14,586,000 13,711,000 13,012,000 11,735,000 11,068,000 9,842,000 8,445,000 
  income from operations-27,300,000 111,240,000 -13,653,000 -30,003,000 -29,342,000 -28,372,000 -29,586,000 -27,234,000 -33,262,000 -24,690,000 -27,176,000 -27,148,000 -25,238,000 -24,795,000 -24,526,000 -22,683,000 -22,029,000 -16,827,000 -14,586,000 -13,711,000 -13,012,000 -11,735,000 -11,068,000 -9,842,000 -8,445,000 
  yoy-6.96% -492.08% -53.85% 10.17% -11.79% 14.91% 8.87% 0.32% 31.79% -0.42% 10.80% 19.68% 14.57% 47.35% 68.15% 65.44% 69.30% 43.39% 31.79% 39.31% 54.08%     
  qoq-124.54% -914.77% -54.49% 2.25% 3.42% -4.10% 8.64% -18.12% 34.72% -9.15% 0.10% 7.57% 1.79% 1.10% 8.13% 2.97% 30.91% 15.36% 6.38% 5.37% 10.88% 6.03% 12.46% 16.54%  
  operating margin %-197.58% 70.15% -60.37% -613.06% -607.37% -672.96% -1055.89% -823.28% 1340.67% -479.23% -831.58% -934.53% -781.12% -826.50%            
  other income:                         
  interest income3,789,000 2,889,000 2,970,000 3,545,000 3,695,000 2,426,000 2,587,000 2,651,000 2,567,000 2,103,000 1,479,000 995,000 544,000 104,000 36,000 44,000 34,000 18,000 10,000 11,000 50,000 674,000 904,000 1,236,000 629,000 
  other income28,000 28,000 201,000 28,000 -48,000 -428,000 41,000 41,000 41,000 42,000 42,000 42,000 42,000 42,000 42,000 42,000 28,000 16,000 15,000 16,000 3,000 22,000 4,000 2,000 -3,000 
  total other income3,817,000 2,917,000 3,171,000 3,573,000 3,647,000 1,998,000 2,628,000 2,692,000 2,608,000 2,145,000 1,521,000 1,037,000 586,000 146,000 78,000 86,000 62,000 34,000 25,000 27,000 53,000 696,000 908,000 1,238,000 626,000 
  income before income taxes-23,483,000 114,157,000                        
  benefit from income taxes 1,278,000                        
  net income-23,483,000 112,879,000 -10,482,000 -26,430,000 -25,695,000 -26,374,000 -26,958,000 -24,542,000 -30,654,000 -22,545,000 -25,655,000 -26,111,000 -24,652,000 -24,649,000 -24,448,000 -22,597,000 -21,967,000        -7,819,000 
  yoy-8.61% -527.99% -61.12% 7.69% -16.18% 16.98% 5.08% -6.01% 24.35% -8.54% 4.94% 15.55% 12.22%             
  qoq-120.80% -1176.88% -60.34% 2.86% -2.57% -2.17% 9.84% -19.94% 35.97% -12.12% -1.75% 5.92% 0.01% 0.82% 8.19% 2.87%          
  net income margin %-169.96% 71.19% -46.35% -540.05% -531.88% -625.57% -962.10% -741.90% 1235.55% -437.60% -785.04% -898.83% -762.98% -821.63%            
  net income per share  -0.17 -0.47 -0.46 -0.57 -0.6 -0.55 -0.69 -0.53 -0.65 -0.66 -0.63 -0.66 -0.67 -0.61 -0.6 -0.46 -0.42 -0.41 -0.39 -0.34 -0.09 -0.26 -1.54 
  basic-0.4 1.95                        
  diluted-0.4 1.9                        
  weighted-average common shares outstanding:                         
  basic58,353,855 57,862,674                        
  diluted58,353,855 59,398,600                        
  comprehensive income:                         
  other comprehensive gain:                         
  unrealized gain on marketable securities200 47 -317 181 -15 24 123 232 219 577 -383.75 -427  -516 -5.5 20          
  total other comprehensive gain200 47 -317 181 -15 24                    
  comprehensive income-23,283 112,926                        
  net income per share  -0.17 -0.47 -0.46 -0.57 -0.6 -0.55 -0.69 -0.53 -0.65 -0.66 -0.63 -0.66 -0.67 -0.61 -0.6 -0.46 -0.42 -0.41 -0.39 -0.34 -0.09 -0.26 -1.54 
  weighted-average common shares outstanding, basic and diluted   56,341,074 55,765,948 46,246,889  44,266,017 44,188,464 42,536,474  39,420,310 39,258,358 37,448,301  36,759,319 36,708,188 36,643,205  33,273,597 33,054,656 32,897,395  32,707,647 5,083,620 
  comprehensive loss:                         
  comprehensive loss  -10,799 -26,249 -25,710 -26,350 -26,835 -24,310 -30,435 -21,968 -25,127 -26,538 -25,244 -25,165 -24,594 -22,577 -21,925         
  total other comprehensive loss      257 232 219 577 528 -427 -592 -516 -146 20 -42         
  other comprehensive loss:                         
  unrealized loss on marketable securities            -592    -42         
  net income and comprehensive loss                 -16,793,000 -14,561,000 -13,684,000 -12,959,000 -11,039,000 -10,160,000 -8,604,000  

We provide you with 20 years income statements for Stoke Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Stoke Therapeutics stock. Explore the full financial landscape of Stoke Therapeutics stock with our expertly curated income statements.

The information provided in this report about Stoke Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.